AI assistant
Sending…
Marker Therapeutics, Inc. — Director's Dealing 2021
Jun 10, 2021
35150_dirs_2021-06-10_56ed4803-5317-4f7b-a8a6-73d8fa086b55.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Marker Therapeutics, Inc. (MRKR)
CIK: 0001094038
Period of Report: 2021-06-08
Reporting Person: Wilson John Robert (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-06-08 | Common Stock | A | 12658 | $0.00 | Acquired | 7812008 | Direct |
Footnotes
F1: Represents the portion of the annual board retainer for each non-employee director payable in immediately vested common stock under the Company's 2020 Equity Incentive Plan and based on the closing price of $3.16 per share, on the day immediately preceding the date of the Company's 2021 annual meeting.
More from Marker Therapeutics, Inc.
Interim / Quarterly Report
2026
May 15
Regulatory Filings
2026
Mar 20
Annual Report
2026
Mar 20
Proxy Solicitation & Information Statement
2026
Mar 20
Annual Report
2026
Mar 18
Regulatory Filings
2026
Feb 9
Director's Dealing
2025
Nov 19
Director's Dealing
2025
Nov 19
Director's Dealing
2025
Nov 19
Major Shareholding Notification
2025
Nov 17